ProteinQure Analysis: $16M Raised
What is ProteinQure?
AI-designed peptides for tissue-specific cancer therapy
HQ Country
Toronto, Canada
Employees
11-50
Founded
2017
HQ State/Province
Ontario
Funding Category
Series A
HQ Full Address
Toronto, Ontario, Canada
Product Features & Capabilities
- ProteinStudio™ AI platform for de novo peptide design
- PQ203 peptide-drug conjugate in Phase I clinical trial for advanced solid tumors
- Tissue-specific delivery system targeting SORT1 receptor in cancer cells
Other Considerations
First patient dosed in Phase I clinical trial of PQ203 in advanced metastatic cancer; Validated by AstraZeneca and UHN Princess Margaret Cancer Centre; Partnerships with pharma and academic research institutions; Proprietary ProteinStudio™ platform with petascale computing capabilities
